Meeting News CoverageVideo

Therapy with vismodegib effective in locally advanced, metastatic basal cell carcinoma

NEW YORK — In this video, Rogerio I. Neves, MD, PhD, FACS, presents data from a single-center study in which the hedgehog inhibitor, vismodegib, demonstrated encouraging activity in patients with basal cell carcinoma.

Vismodegib (Erivedge, Genentech) binds to and inhibits smoothened homologue, a transmembrane protein involved in hedgehog signal transduction, according to background information in the study.

Neves and colleagues from the departments of plastic surgery, dermatology and medical oncology at Penn State Hershey Cancer Institute in Hershey, Pa., evaluated results of patients with locally advanced basal cell carcinoma or metastatic basal cell carcinoma treated with vismodegib between April 2012 and December 2013.

NEW YORK — In this video, Rogerio I. Neves, MD, PhD, FACS, presents data from a single-center study in which the hedgehog inhibitor, vismodegib, demonstrated encouraging activity in patients with basal cell carcinoma.

Vismodegib (Erivedge, Genentech) binds to and inhibits smoothened homologue, a transmembrane protein involved in hedgehog signal transduction, according to background information in the study.

Neves and colleagues from the departments of plastic surgery, dermatology and medical oncology at Penn State Hershey Cancer Institute in Hershey, Pa., evaluated results of patients with locally advanced basal cell carcinoma or metastatic basal cell carcinoma treated with vismodegib between April 2012 and December 2013.

    See more from HemOnc Today New York